ArticleBMC infectious diseases2020
Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010-2016.
Article in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- German evidence- and consensus-based guideline on the management of penile urethritis.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Guideline
- HIV Testing Uptake According to Opt-In, Opt-Out or Risk-Based Testing Approaches: a Systematic Review and Meta-Analysis.Current HIV/AIDS reports · 2022Pooled it
- HIV/AIDS late presentation and its associated factors in China from 2010 to 2020: a systematic review and meta-analysis.AIDS research and therapy · 2021Pooled it
- Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial.Nature communications · 2026Trial
- Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Late-Presenting People With HIV-1 Infection.Open forum infectious diseases · 2024Trial
- Tracing the patterns of HIV-1 transmission among people with different diagnosis status in Greece.Virus research · 2026Article
- Multi-country study on the impact of a revised consensus definition of late HIV diagnosis, Europe, 2022 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Scoping review of patient and family engagement interventions in diagnosis: a paradox of too much, yet so little.BMJ quality & safety · 2026Article
- New HIV diagnoses and risk factors for late HIV diagnosis, Finland, 2008-2023.Epidemiology and infection · 2026Article
- Expert consensus on the clinical management of HIV late presentation.Infectious diseases & immunity · 2026Article
- Late diagnosis of paediatric HIV infection in high-income countries: Lessons from the HIV Perinatal Virtual Clinic.HIV medicine · 2026Article
- Risk factors for late HIV diagnosis in England, 2015-2023.HIV medicine · 2026Article
- Pathological Proliferation of CD4Infection and drug resistance · 2026Article
- Protective association of theFrontiers in medicine · 2026Article
- HIV-1 late diagnosis in Cabo Verde: associated factors and implications for preventive strategies.Frontiers in epidemiology · 2026Article
- Refractory Dermatophytosis and Oral Hairy Leukoplakia as Sentinel Manifestations of Advanced HIV Infection.Cureus · 2025Article
- Progressive multifocal leukoencephalopathy as a rare first manifestation of AIDS: case report.Postepy psychiatrii neurologii · 2025Article
- Evaluation of HIV Late Presentation Trends: A Cross-Sectional Analysis from a Leading Ecuadorian Public Hospital.Pathogens (Basel, Switzerland) · 2025Article
- Use of healthcare services preceding HIV diagnosis - missed opportunities for earlier diagnosis, Finland, 1996 to 2019.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Association between cytokine and increased risk of death in ART- naïve and ART-non-adherence patients hospitalized with advanced HIV disease.BMC infectious diseases · 2025Observational
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLate presentation (LP), defined as a CD4 count < 350/mm
methodsCountry-specific percentages of LP and AIDS-events/death rates (assessed with Poisson regression) observed in The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) and EuroSIDA cohorts, were applied to new HIV-diagnoses reported to the European Centre for Disease Prevention and Control. The estimated number of LP in the whole population was then calculated, as was the number of excess AIDS-events/deaths in the first 12 months following HIV-diagnosis assumed to be attributable to LP (difference in estimated events between LP and non-LP).
resultsThirty-nine thousand two hundred four persons were included from the COHERE and EuroSIDA cohorts, of whom 18,967 (48.4%; 95% Confidence Interval [CI] 47.9-48.9) were classified as LP, ranging from 36.9% in Estonia (95%CI 25.2-48.7) and Ukraine (95%CI 30.0-43.8) to 64.2% in Poland (95%CI 57.2-71.3). We estimated a total of > 320,000 LP and 12,050 new AIDS-events/deaths attributable to LP during 2010-2016, with the highest estimated numbers of LP and excess AIDS-events/deaths in Eastern Europe. Country-level estimates of excess events ranged from 17 AIDS-events/deaths (95%CI 0-533) in Denmark to 10,357 (95%CI 7768-147,448) in Russia.
conclusionsAcross countries in Europe, the burden of LP was high, with the highest estimated number of LP and excess AIDS-events/deaths being in Eastern Europe. Effective strategies are needed to reduce LP and the attributable morbidity and mortality that could be potentially avoided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.